IL1B and in situ carcinoma: Administration of either kinetin in different concentrations of 0.25, 0.5 or 1 mg/kg, or vitamin C, caused significant protection against the up-regulation in testicular TNF-α, IL-1β and IL-6 levels of CIS-treated rats.